<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Krueger, James</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">IL-23 Blockade with BI 655066 Improves PASI in Psoriasis</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">12-13</style></pages><abstract><style  face="normal" font="default" size="100%">Secretion of interleukin (IL)-23 by myeloid dendritic cells plays a role in the initiation of psoriasis. In addition, chronic psoriasis is maintained, at least in part, by the continued secretion of IL-23, which promotes the secretion of chemokines and antimicrobial peptides by keratinocytes, resulting in amplification that causes further IL-23 secretion. This article discusses the combination of IL-23 blockade with a single dose of the monoclonal antibody BI 655066 in the Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis [NCT01577550].</style></abstract><number><style face="normal" font="default" size="100%">37</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>